Format

Send to

Choose Destination
Int J Mol Sci. 2018 Aug 25;19(9). pii: E2516. doi: 10.3390/ijms19092516.

Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target.

Author information

1
Department of Microbiological and Nanobiomedical Engineering, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland. ewelina.piktel@wp.pl.
2
McGovern Medical School, University of Texas Health Science Center, Houston MSB 4.202A, 6431 Fannin St, Houston, TX 77096, USA. Ilya.Levental@uth.tmc.edu.
3
Department of Microbiology and Immunology, The Faculty of Medicine and Health Sciences of the Jan Kochanowski University in Kielce, Aleja IX Wieków Kielc, 25-317 Kielce, Poland. Bonita.Durnas@onkol.kielce.pl.
4
Institute for Medicine and Engineering, University of Pennsylvania, 3340 Smith Walk, Philadelphia, PA 19104, USA. janmey@mail.med.upenn.edu.
5
Department of Microbiological and Nanobiomedical Engineering, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland. buckirobert@gmail.com.

Abstract

Gelsolin, an actin-depolymerizing protein expressed both in extracellular fluids and in the cytoplasm of a majority of human cells, has been recently implicated in a variety of both physiological and pathological processes. Its extracellular isoform, called plasma gelsolin (pGSN), is present in blood, cerebrospinal fluid, milk, urine, and other extracellular fluids. This isoform has been recognized as a potential biomarker of inflammatory-associated medical conditions, allowing for the prediction of illness severity, recovery, efficacy of treatment, and clinical outcome. A compelling number of animal studies also demonstrate a broad spectrum of beneficial effects mediated by gelsolin, suggesting therapeutic utility for extracellular recombinant gelsolin. In the review, we summarize the current data related to the potential of pGSN as an inflammatory predictor and therapeutic target, discuss gelsolin-mediated mechanisms of action, and highlight recent progress in the clinical use of pGSN.

KEYWORDS:

actin; biomarker; extracellular recombinant gelsolin; inflammation; plasma gelsolin

PMID:
30149613
PMCID:
PMC6164782
DOI:
10.3390/ijms19092516
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center